Mirion Technologies Baird 2026 Global Industrial Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good afternoon, and thanks, everyone, for joining us for the Mirion Technologies session. I'm Quinn Fredrickson, Senior Research Analyst at Baird, covering advanced industrial technology. Mirion is the global leader in detection and measurement technologies for sensing ionizing radiation in the nuclear power end market, as well as a leader in radiation therapy, quality assurance, dosimetry, and nuclear medicine. With us this afternoon to discuss Mirion is Tom Logan, who is the founder, chairman, and CEO, and Brian Schopfer, who is the Chief Financial Officer. I'm going to hand it off first to Tom for some introductory comments and some slides about Mirion, and then we'll come back for Q&A.
Quinn, thank you. Thanks to everybody for joining us this afternoon. I'm going to give you two brief panels as an overview regarding who we are, what we do, and what our areas of focus are. Firstly, to begin with, Mirion is, in our view, the global leader in ionizing radiation detection and measurement, as Quinn noted. Today, we're organized into two operating segments. Our largest segment is our nuclear and safety business. This represents about 70% of our total revenue, and within that, there are three key sectors that we serve. Far and away, the largest is commercial nuclear power, and following that, we have significant presence in labs and research, and defense and diversified. Our second group, medical, is about 30% of our total revenue, and here again, we have three sectors.
We have radiation therapy delivered externally, so think of a linear accelerator, a LINAC, or other external beam therapy modalities. Nuclear medicine, where we play a significant role in the overall value chain, ranging from diagnostic and therapeutic instruments through compounding equipment, dose calibration instruments, and the like. Then finally, we have our dosimetry services, which you can think of as an outsourced subscription service, which supports healthcare professionals, keeps them safe from ionizing radiation. The big story, I think what everybody is focused on right now, is nuclear power. Clearly, the world is undergoing a major shift in energy balance, and the focus on nuclear power as a component of the overall mix certainly has elevated notably over the last two to three years.
Importantly, Mirion today gets nearly half of its total revenue from commercial nuclear power, with a presence in more than 98% of the global operating fleet, representing roughly 450 reactors. So, we are broadly diversified globally, have a significant presence across that footprint, and importantly, 80% of our nuclear power-related revenue comes from the installed base. This is a critical attribute of our business, and I'm sure as we get into Q&A, we will talk about our exposure to data center build-out and a variety of other measures, but I just want to anchor you on this key fact that, again, 80% of our revenue comes from the installed base. With that, Quinn, over to you for Q&A.
Yep. For the audience, if you have any questions, you can send it to session3@rwbaird.com, and we'll field those from the iPad. I think just to start off, might be helpful to level set the group on the third quarter print. I think the things that stood out to me, 62% organic orders growth, overall organic revenue growth accelerated to 6.5%, strength in nuclear power end market, specifically with 14% organic growth. Maybe if you could just unpack a little bit what drove the strength in that third quarter, and then the factors that support further strengthening in your fourth quarter outlook.
Yeah, I think the key factors, firstly, the order dynamics really were comprehensive, not narrowly confined to a specific segment or specific component of that segment overall. I think the key overall drivers that we're seeing here are things that we've been foreshadowing for some period of time. Firstly, when we look at nuclear, again, roughly half of our total business, and again, reflecting on this anchor that 80% of our nuclear business comes from the installed fleet.
What we have been seeing is a significant growth in capital commitments to that installed base overall, recognizing that these are assets that have gone from being challenged a decade ago, with difficult supply and demand dynamics in the electrical generating markets overall, poor margins, regimes of extreme capital rationing, to where we are today, where the world faces a profound shortage of electrical generating capacity that candidly is not solvable in the near term. That has fundamentally changed the economics of owning and operating a nuclear power plant, and as a consequence, the operators have been very motivated to maximize the benefit of these assets. That's happened in a number of ways. Firstly, as it relates to the capital commitment necessary to remediate some of the capital rationing that took place over the prior decade.
Secondly, through life extension and power uprates, meaning extending the permitted operating envelope of those plants, but also getting a more permitted capacity out of those power plants. Then finally, we are beginning to see a higher degree of digital modernization. We've seen this flow into orders, Quinn, as you noted. We've seen strong, not only order growth, but organic revenue growth in this sector, and I think that is clearly a sign of strengthening momentum in the sector overall. Importantly, the signal, the binary gateway that has been passed through here really is reflected in that permitting activity. This is a dynamic that, again, is not exposed to the rate of data center build-out. It's not exposed to political winds. Essentially, the bell has been rung, and in our view, we're looking at a decade or more of strong capital spending growth in this sector overall.
Beyond that, as we look at the other element of nuclear, which is new build activity, we were happy to have booked a very large new build utility scale order in Egypt. We are also happy that we have seen growth in the small modular reactor market, which has grown over the last year from roughly just over 1% of our revenue to closer to 4% of our revenue overall. Importantly, this revenue, in the main, is tied to the leading players in the SMR market overall. These are companies that have raised significant capital, have a high degree of technological readiness, and in our view, importantly, they are going to be very focused on deploying that capital as quickly as they can to prove the validity of their first-of-a-kind reactors.
Turning to the medical segment here, we have seen recovery in the two major verticals or two major sub-segments within this, in both radiation therapy, where we are beginning, in our view, to see a normalization of the post-COVID dynamic that has created a bit of flatness in growth overall in the med tech sector. We are beginning to see that come off the peg and, we believe, normalize. Similarly, in nuclear medicine, we are seeing a pickup in activity, and here, the big driver is the advent, the evolution, the growth in the so-called theranostic space overall. Lastly, in our dosimetry market, we continue to see solid service revenue growth, which is really the core of that business overall. None of this is surprising to us.
It is certainly gratifying to see a tighter correlation between our backlog growth, which has led our organic revenue growth, and the conditions feel durable to us.
Touched on a number of drivers there that I want to explore more, but start off on catch-up CapEx. What inning do you think we are there, and does that manifest more in the U.S. versus the rest of the world? I think you have discussed Paragon's peaks business is where you are seeing the benefits of that most concretely, so I presume it is more of a North American tailwind. Is that the right way to think about it?
We would actually characterize it as a global phenomenon, recognizing that the writ large, the factors that led to this prolonged capital rationing really have been global in nature, driven by a variety of supply-side and demand-side dynamics. Our view is that we're still in the early innings here. Certainly, Paragon for us is the canary in the coal mine. For those of you not less familiar with the company, Paragon is an asset that we acquired just under a year ago, and the core of their business is supplying spare electromechanical components into the North American operating fleet overall. Paragon organically grew 20% last year. This year, we've guided 25% organic growth for Paragon, and I think this is the strongest possible indication of the dynamic that we are seeing, again, based on that or driven by that catch-up capital spend.
There's also been a lot of momentum with a number of headlines on life extensions and power uprates recently across multiple hyperscalers. Just curious if the urgency of bringing those uprates online for the hyperscalers accelerates the order to revenue conversion opportunity for Mirion.
Yeah, there certainly is a great deal of urgency as it relates to the uprates. On our earnings call a couple of weeks ago, we talked about the fact that their recent announcements amount to about 2 GW of operated capacity. That essentially represents two new nuclear power plants. Certainly, the hyperscalers are the hungriest for that incremental power overall. It is reflective of a dynamic within the North American nuclear industry where the highest priority for capital spending today is anything that will generate an additional megawatt of capacity overall. To be clear, there's a very high degree of urgency there overall.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
